Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming het aandeel van 2017

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,716   +0,021   (+3,02%) Dagrange 0,691 - 0,716 3.985.580   Gem. (3M) 4,8M

Pharming het aandeel van 2017

Volgen
50.750 Posts
Pagina: «« 1 ... 2226 2227 2228 2229 2230 ... 2538 »» | Laatste | Omlaag ↓
  6. [verwijderd] 23 oktober 2017 07:38
    quote:

    't zal maar gebeuren schreef op 23 oktober 2017 07:24:

    Pharming oefent warrants uit

    Gepubliceerd op 23 okt 2017 om 07:17 | Views: 0 | Onderwerpen: biotechnologie

    Artikel
    Reacties
    Gerelateerde instrumenten

    Pharming 20 okt
    0,71 +0,05 (+8,23%)

    LEIDEN (AFN) - Pharming heeft de afgelopen periode 12,5 miljoen nieuwe aandelen uitgegeven. Het biotechbedrijf deed dat sinds 10 augustus vanwege de uitoefening van warrants en opties en de conversie van obligaties.

    De nieuw uitgegeven aandelen zijn goed voor 1,5 procent van het uitstaande aandelenkapitaal. Het ging om een converteerbare obligatielening met een looptijd tot 2021. Daarvan heeft Pharming nu 11,5 miljoen euro uitstaan.

    benieuwd wie die opties heeft uitgeoefend.
    Bij de opties gaat het om deze hoeveelheden:
    Aan houders van opties
    Aandelen vertegenwoordigd door uitgeoefende opties 340.000
    Aandelen uitgegeven door niet-contante uitoefening 167.576

    (van 50.314.588 naar 49.964.588)
  11. [verwijderd] 23 oktober 2017 07:41
    LEIDEN (AFN) - Pharming heeft de afgelopen periode 12,5 miljoen nieuwe aandelen uitgegeven. Het biotechbedrijf deed dat sinds 10 augustus vanwege de uitoefening van warrants en opties en de conversie van obligaties.
    De nieuw uitgegeven aandelen zijn goed voor 1,5 procent van het uitstaande aandelenkapitaal. Het ging om een converteerbare obligatielening met een looptijd tot 2021. Daarvan heeft Pharming nu 11,5 miljoen euro uitstaan.
  15. [verwijderd] 23 oktober 2017 07:46
    Pharming announces warrant exercises and conversions of its Ordinary Bonds into shares mostly through cashless exercise

    Net result is a reduction of the fully diluted share capital by 8,212,468 shares
    • Total number of shares issued in warrant exercises, option exercises and bond conversions since the last update on 10 August 2017 is 12,548,663 ordinary shares
    • Number of warrants and options exercisable has been reduced by 20,320,993 to 30,489,893 which represents less than 5.8% of the outstanding shares
    • 8,212,468 shares recovered through cashless exercise represent 1.5% of the issued share capital, and therefore 1.5% lower dilution of shareholders in the future
    • Cash receipts from these latest exercises total €0.5 million
    • Amount of Ordinary Bonds due 2021 has been reduced further from €11.6 million to €11.5 million

    Leiden, The Netherlands, 23 October 2017: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT: PHARM) today announced that since the release of its update regarding cashless and other warrant exercises and bond conversions on 10 August 2017, it has issued 12,548,663 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares. These shares were issued as follows:

    • To Holders of the 2016 warrants
    Shares represented by warrants exercised 19,980,993
    Shares issued as a result of cashless exercise: 11,940,949
    Shares recovered (and not issued) through cashless exercise: 8,040,044
    Representing 1.5% of the issued share capital after the exercise

    • To Holders of the Ordinary Convertible Bonds due 2021
    Shares represented by bonds converted 440,138
    Value of Bonds redeemed: €0.1 million
    As result of these conversions, the total amount outstanding of the Ordinary Bonds has been reduced from €11.6 million to €11.5 million.

    • To Holders of Options
    Shares represented by options exercised 340,000
    Shares issued as a result of cashless exercise: 167,576

    The new shares issued represent 2.42% of the issued share capital of the Company at 10 August 2017 (the date of the last statement of issued share capital) and 2.37% of the enlarged share capital following the issue. The revised issued share capital of the Company following this issue is 530,222,689 shares. This exercise has resulted in an increase of the uncommitted share capital headroom by 8,212,468 shares to 141,174,961 shares. The numbers of shares, warrants and other share rights outstanding as well as authorized share capital as per the date of this press release are provided in the following table.

    22 October 2017 10 August 2017
    Shares issued 530,222,689 517,674,026
    Shares committed:
    Warrants 30,489,893 50,470,886
    Convertible Bonds 40,404,932 40,845,070
    Options 49,964,588 50,304,588
    LTIP 7,742,937 7,742,937
    Total committed 128,602,350 149,363,481

    Issued and committed (Fully Diluted) 658,825,039 667,037,507

    Available for issue (uncommitted share capital headroom) 141,174,961 132,962,493

    Authorised share capital 800,000,000 800,000,000

    About Pharming Group N.V.

    Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

    RUCONEST® is commercialized by Pharming in Algeria, Andorra, Austria, Bahrain, Belgium, France, Germany, Ireland, Jordan, Kuwait, Lebanon, Luxembourg, Morocco, the Netherlands, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, the United Arab Emirates, the United Kingdom, the United States of America and Yemen.

    RUCONEST® is distributed by Swedish Orphan Biovitrum AB (publ) (SS: SOBI) in the other EU countries, and in Azerbaijan, Belarus, Georgia, Iceland, Kazakhstan, Liechtenstein, Norway, Russia, Serbia and Ukraine.

    RUCONEST® is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama, and Venezuela by Cytobioteck, in South Korea by HyupJin Corporation and in Israel by Megapharm.

    RUCONEST® has recently completed a clinical trial for the treatment of HAE in young children (2-13 years of age) and is also evaluated for various additional follow-on indications.

    Additional information is available on the Pharming website: www.pharming.com

    Forward-looking Statements

    This press release of Pharming Group N.V. and its subsidiaries (“Pharming”, the “Company” or the “Group”) may contain forward-looking statements including without limitation those regarding Pharming’s financial projections, market expectations, developments, partnerships, plans, strategies and capital expenditures.

    The Company cautions that such forward-looking statements may involve certain risks and uncertainties, and actual results may differ. Risks and uncertainties include without limitation the effect of competitive, political and economic factors, legal claims, the Company’s ability to protect intellectual property, fluctuations in exchange and interest rates, changes in taxation laws or rates, changes in legislation or accountancy practices and the Company’s ability to identify, develop and successfully commercialize new products, markets or technologies.

    As a result, the Company’s actual performance, position and financial results and statements may differ materially from the plans, goals and expectations set forth in such forward-looking statements. The Company assumes no obligation to update any forward-looking statements or information, which should be taken as of their respective dates of issue, unless required by laws or regulations.


50.750 Posts
Pagina: «« 1 ... 2226 2227 2228 2229 2230 ... 2538 »» | Laatste |Omhoog ↑

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: volop groeimotoren voor Pharming
  2. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  3. Topman De Vries stopt bij Pharming
  4. Pharming start met Fase II klinische studie leniolisib
  5. Pharming: herstelpotentieel van 100%
  6. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak
  7. Micron-effect op de beurs? AEX gaat fraaie opening tegemoet, chipaandelen Azië vliegen
  8. Brits groen licht voor Joenja van Pharming
  9. Video: CEO tevreden over ontwikkelingen bij Pharming
  10. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10